Marker Therapeutics, INC 10-Q quarterly reports

Marker Therapeutics reports a net loss of $3.2 million for Q1 2026 while maintaining a cash runway into Q1 2027.

Marker Therapeutics reported a reduced net loss for the third quarter of 2025, driven by decreased R&D expenses, while also highlighting positive clinical data from its APOLLO study and securing new manufacturing partnerships amidst a 'going concern' warning.

Marker Therapeutics, a clinical-stage immuno-oncology company, reported a significantly wider net loss for Q2 2025 and issued a going concern warning, despite positive early clinical data for its lead therapy MT-601 and recent capital raises.

Marker Therapeutics' Q1 2025 results show a net loss, decreased grant revenue, and ongoing efforts to secure additional funding for clinical trials.

Marker Therapeutics reported its Q3 2024 financial results, highlighting increased grant revenue and reduced operating expenses, while continuing to advance its clinical-stage immuno-oncology programs.

Marker Therapeutics reported its second quarter 2024 financial results, highlighting a decrease in operating expenses and progress in its clinical programs.

Marker Therapeutics reported a net loss of $2.39 million for the first quarter of 2024, while highlighting ongoing clinical program advancements and cost reductions.